Literature DB >> 26666925

Activity of Eravacycline against Escherichia coli Clinical Isolates Collected from U.S. Veterans in 2011 in Relation to Coresistance Phenotype and Sequence Type 131 Genotype.

James R Johnson1, Stephen B Porter2, Brian D Johnston3, Paul Thuras3.   

Abstract

Eravacycline is a novel broad-spectrum fluorocycline with potent Gram-negative activity, including for multidrug-resistant strains. Among 472 Escherichia coli clinical isolates from 24 Veterans Affairs medical centers (in 2011), divided equally as susceptible versus resistant to fluoroquinolones, broth microdilution eravacycline MICs were distributed unimodally, ranging from 0.03 to 1.0 μg/ml (MIC50 of 0.125 μg/ml, MIC90 of 0.25 μg/ml). Eravacycline MICs were ∼ 2-fold higher among fluoroquinolone-resistant, gentamicin-resistant, multidrug-resistant, and sequence type 131 (ST131) isolates (P < 0.01 for each comparison).
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26666925      PMCID： PMC4775941          DOI： 10.1128/AAC.02403-15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  14 in total

Review 1.  Escherichia coli ST131, an intriguing clonal group.

Authors:  Marie-Hélène Nicolas-Chanoine; Xavier Bertrand; Jean-Yves Madec
Journal:  Clin Microbiol Rev       Date:  2014-07       Impact factor: 26.132

2.  Escherichia coli sequence type ST131 as the major cause of serious multidrug-resistant E. coli infections in the United States.

Authors:  James R Johnson; Brian Johnston; Connie Clabots; Michael A Kuskowski; Mariana Castanheira
Journal:  Clin Infect Dis       Date:  2010-08-01       Impact factor: 9.079

3.  Escherichia coli sequence type 131 (ST131) subclone H30 as an emergent multidrug-resistant pathogen among US veterans.

Authors:  Aylin Colpan; Brian Johnston; Stephen Porter; Connie Clabots; Ruth Anway; Lao Thao; Michael A Kuskowski; Veronika Tchesnokova; Evgeni V Sokurenko; James R Johnson
Journal:  Clin Infect Dis       Date:  2013-08-06       Impact factor: 9.079

4.  Molecular epidemiological analysis of Escherichia coli sequence type ST131 (O25:H4) and blaCTX-M-15 among extended-spectrum-β-lactamase-producing E. coli from the United States, 2000 to 2009.

Authors:  James R Johnson; Carl Urban; Scott J Weissman; James H Jorgensen; James S Lewis; Glen Hansen; Paul H Edelstein; Ari Robicsek; Timothy Cleary; Javier Adachi; David Paterson; John Quinn; Nancy D Hanson; Brian D Johnston; Connie Clabots; Michael A Kuskowski
Journal:  Antimicrob Agents Chemother       Date:  2012-02-21       Impact factor: 5.191

5.  Abrupt emergence of a single dominant multidrug-resistant strain of Escherichia coli.

Authors:  James R Johnson; Veronika Tchesnokova; Brian Johnston; Connie Clabots; Pacita L Roberts; Mariya Billig; Kim Riddell; Peggy Rogers; Xuan Qin; Susan Butler-Wu; Lance B Price; Maliha Aziz; Marie-Hélène Nicolas-Chanoine; Chitrita Debroy; Ari Robicsek; Glen Hansen; Carl Urban; Joanne Platell; Darren J Trott; George Zhanel; Scott J Weissman; Brad T Cookson; Ferric C Fang; Ajit P Limaye; Delia Scholes; Sujay Chattopadhyay; David C Hooper; Evgeni V Sokurenko
Journal:  J Infect Dis       Date:  2013-01-03       Impact factor: 5.226

6.  Prevalence and characteristics of the epidemic multiresistant Escherichia coli ST131 clonal group among extended-spectrum beta-lactamase-producing E. coli isolates in Copenhagen, Denmark.

Authors:  Bente Olesen; Dennis S Hansen; Frida Nilsson; Jakob Frimodt-Møller; Rikke Fleron Leihof; Carsten Struve; Flemming Scheutz; Brian Johnston; Karen A Krogfelt; James R Johnson
Journal:  J Clin Microbiol       Date:  2013-04-03       Impact factor: 5.948

7.  Phase 2, randomized, double-blind study of the efficacy and safety of two dose regimens of eravacycline versus ertapenem for adult community-acquired complicated intra-abdominal infections.

Authors:  Joseph S Solomkin; Mayakonda Krishnamurthy Ramesh; Gintaras Cesnauskas; Nikolajs Novikovs; Penka Stefanova; Joyce A Sutcliffe; Susannah M Walpole; Patrick T Horn
Journal:  Antimicrob Agents Chemother       Date:  2013-12-16       Impact factor: 5.191

8.  Molecular epidemiology of Escherichia coli sequence type 131 and Its H30 and H30-Rx subclones among extended-spectrum-β-lactamase-positive and -negative E. coli clinical isolates from the Chicago Region, 2007 to 2010.

Authors:  Ritu Banerjee; Ari Robicsek; Michael A Kuskowski; Stephen Porter; Brian D Johnston; Evgeni Sokurenko; Veronika Tchesnokova; Lance B Price; James R Johnson
Journal:  Antimicrob Agents Chemother       Date:  2013-09-30       Impact factor: 5.191

9.  Antibacterial activity of eravacycline (TP-434), a novel fluorocycline, against hospital and community pathogens.

Authors:  J A Sutcliffe; W O'Brien; C Fyfe; T H Grossman
Journal:  Antimicrob Agents Chemother       Date:  2013-08-26       Impact factor: 5.191

10.  The epidemic of extended-spectrum-β-lactamase-producing Escherichia coli ST131 is driven by a single highly pathogenic subclone, H30-Rx.

Authors:  Lance B Price; James R Johnson; Maliha Aziz; Connie Clabots; Brian Johnston; Veronika Tchesnokova; Lora Nordstrom; Maria Billig; Sujay Chattopadhyay; Marc Stegger; Paal S Andersen; Talima Pearson; Kim Riddell; Peggy Rogers; Delia Scholes; Barbara Kahl; Paul Keim; Evgeni V Sokurenko
Journal:  mBio       Date:  2013-12-17       Impact factor: 7.867
View more
  5 in total

1.  Activity of Cefiderocol, Ceftazidime-Avibactam, and Eravacycline against Carbapenem-Resistant Escherichia coli Isolates from the United States and International Sites in Relation to Clonal Background, Resistance Genes, Coresistance, and Region.

Authors:  Brian D Johnston; Paul Thuras; Stephen B Porter; Melissa Anacker; Brittany VonBank; Paula Snippes Vagnone; Medora Witwer; Mariana Castanheira; James R Johnson
Journal:  Antimicrob Agents Chemother       Date:  2020-09-21       Impact factor: 5.191

2.  In vitro susceptibility of β-lactamase-producing carbapenem-resistant Enterobacteriaceae (CRE) to eravacycline.

Authors:  Yunliang Zhang; Xiaoyan Lin; Karen Bush
Journal:  J Antibiot (Tokyo)       Date:  2016-06-29       Impact factor: 2.649

3.  Randomized, Double-Blind, Placebo-Controlled Studies of the Safety and Pharmacokinetics of Single and Multiple Ascending Doses of Eravacycline.

Authors:  Joseph V Newman; Jian Zhou; Sergey Izmailyan; Larry Tsai
Journal:  Antimicrob Agents Chemother       Date:  2018-10-24       Impact factor: 5.191

4.  In Vitro Activity of Eravacycline against Gram-Positive Bacteria Isolated in Clinical Laboratories Worldwide from 2013 to 2017.

Authors:  Ian Morrissey; Stephen Hawser; Sibylle H Lob; James A Karlowsky; Matteo Bassetti; G Ralph Corey; Melanie Olesky; Joseph Newman; Corey Fyfe
Journal:  Antimicrob Agents Chemother       Date:  2020-02-21       Impact factor: 5.191

5.  In Vitro Activity of Eravacycline against Gram-Negative Bacilli Isolated in Clinical Laboratories Worldwide from 2013 to 2017.

Authors:  Ian Morrissey; Melanie Olesky; Stephen Hawser; Sibylle H Lob; James A Karlowsky; G Ralph Corey; Matteo Bassetti; Corey Fyfe
Journal:  Antimicrob Agents Chemother       Date:  2020-02-21       Impact factor: 5.191
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.